Does dapagliflozin improve clinical outcomes and NYHA functional class in symptomatic patients with heart failure and LVEF >40%?
Dapagliflozin provides clinical benefit and early, sustained improvements in NYHA functional class in patients with heart failure and mildly reduced or preserved ejection fraction.
Among symptomatic patients with HF and LVEF >40%, treatment with dapagliflozin provided clinical benefit irrespective of baseline NYHA class and was associated with early and sustained improvements in NYHA class over time.
Ostrominski et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: